Navigation Links
Enzyme Responsible For Congenital Blindness

Researchers from UCLA had found out that a deficient gene that is also responsible for the presence of an enzyme in the vision cycle that causes congenital blindness in children. The researchers’ study regarding the congenital blinding disease // called Leber congenital amaurosis is published in the August issue of the journal Cell.

Researchers suggest that replacement of RPE65, which is lacking in these patients, by gene therapy should correct the blindness in these children, as was observed in mice and dogs with RPE65 mutations, said the researchers. This is a major breakthrough in understanding the visual cycle. It has ramifications for several inherited blinding diseases caused by mutations in visual cycle genes.

The newly identified isomerase enzyme plays a crucial role in the regeneration of rhodopsin visual pigment in the retina after light exposure. Rhodopsin contains a light-absorbing molecule called 11 cis retinaldehyde, related to vitamin A, which is converted upon light absorption to all trans retinaldehyde in a process called photo bleaching. This conversion is the first step in visual perception.

Photo bleaching leaves the rhodopsin insensitive to light until the all trans retinaldehyde is converted, or "isomerized," back into 11 cis retinaldehyde, which completes the visual cycle. Scientists have for two decades been attempting to identify the retinoid isomerase enzyme that catalyzes this regeneration of 11 cis retinaldehyde. Scientists have also been stumped by the function of the Rpe65 protein

The researchers had performed an expression screen in cultured human cells, looking for a gene that caused these cells to convert vitamin A into 11 cis retinol.

The researchers are now studying the effects on retinoid isomerase activity of specific disease causing mutations in the RPE65 gene, which should provide more data on the cause of Leber congenital amaurosis and on how the Rpe65 protein works. The
'"/>




Page: 1 2

Related medicine news :

1. Enzyme may be target for obesity drugs
2. Researchers trick Alzheimers Enzyme
3. Enzyme stimulates growth of adult stem cells
4. Enzyme may aid hold back disease
5. Enzyme help destroy cancer cell
6. Enzyme Associated with Memory
7. Enzyme Associated With Memory
8. Brain Enzyme Found To Regulate Weight
9. New Enzyme Identified For Arthritis
10. Enzyme for treatment of arthritis
11. An Enzyme That Turns a One –time Experience into a long-time Memor
Post Your Comments:
(Date:7/2/2009)...ngsters with the disease , , THURSDAY, J...betes are more likely to be overweight than those ...ous health complications, researchers say. , Th...weight problems faced by U.S. youngsters with type...t usually shows up in childhood or in young adults...
(Date:7/2/2009)...itis B virus (HBV) are associated with the develop...tients with HBV infections are at increased risk o...in the Journal of the National Cancer Institute ,...nown cause of hepatocellular carcinoma (HCC), the ... have looked at whether patients with specific mut...
(Date:7/2/2009)...y night saw the launch of (RED)ZONES at the first ...d off their new tour to a rapturous sold out crowd...tion areas directly adjacent to the stage which wi... for the (RED)ZONES are available through auction ...to the Global Fund to help fund AIDS programs in A...
(Date:7/2/2009)...hytherapy and remain free of disease for five year...10 years, according to a study in the July 1 issue...gy*Biology*Physics , the official journal of the A...Brachytherapy is the placement of radioactive sour...or temporarily, depending upon the cancer. , In t...
Breaking Medicine News(10 mins):Health News:Kids With Type 1 Diabetes Often Overweight 2Health News:(RED)ZONES Launch at First U2 360 Degrees Concert in Barcelona 2Health News:(RED)ZONES Launch at First U2 360 Degrees Concert in Barcelona 3
...lecular Biology Laboratory (EMBL) and the Universi...s us against a serious kidney disease In the cur...hat mutations in the gene cause nephronopthisis (N...ase marked by kidney degeneration during childhood...
...n died from metal poisoning last year after ingest...e, the B.C. Coroners Service confirmed Thursday A ...buying drugs over the Internet after the death of ...nfirm the pills appear to have killed 57-year-old ...
...would have to consider a radical change in their l...and greener future, a report prepared by the Centr...cording to the report, the lifestyle changes could...ning battery- operated cars and avoiding affordabl...
...pound from olive-pomace oil slows down the spread ... Granada and Hospital Carlos III in Madrid, establ...skin, inhibits serin-protease, the enzyme used by ...ected cell into the extra cellular environment and...
Other Medicine News:Health News:New Therapies for Kidney Diseases 2Health News:Online Counterfeit Pills Kills Woman 2Health News:Radical Change in the Lifestyle Might Bring a Greener Future for Brits 2
(Date:6/25/2009)...OX(R) and EMBEDA (TM) Data Highlighted at the Coll..., , RENO, Nev., June 25 King ...d that the Company is presenting safety and effica...wo novel opioid analgesic formulations that are in...llege on Problems of Drug Dependence. King is als...
(Date:6/24/2009)...LEUVEN, Belgium, June 25 ..., Lead Product for the,Non-Surgical Treatment of ... ThromboGenics NV (Euronext Brussels: THR), a bio...evelopment of innovative treatments for eye,disea...hat its lead product,microplasmin, which is in Ph...
(Date:6/24/2009)...iminary top-line results of second Phase III study...igue and improved daily function in fibromyalgia p...II study , , PALO ALTO, Calif., and BRUSSELS, J...egulated information -- Jazz Pharmaceuticals, Inc...B) announced today positive preliminary top-line r...
(Date:6/24/2009)...TLE, June 24 A Common... Cooperative is structured with incentives align... ways that make the most sense operationally and c...rofiles looking at medical systems that have the a...necessary for a high performing health care system...
Breaking Medicine Technology:King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use 2King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use 3King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use 4King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use 5King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use 6ThromboGenics' Microplasmin Phase III Program Progressing According to Schedule 2ThromboGenics' Microplasmin Phase III Program Progressing According to Schedule 3Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints 2Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints 3Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints 4Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints 5Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints 6Commonwealth Fund Case Study Points to 'Continuous Innovation' at Group Health Cooperative 2Commonwealth Fund Case Study Points to 'Continuous Innovation' at Group Health Cooperative 3Prism glasses expand the view for patients with hemianopia 19103 1Prism glasses expand the view for patients with hemianopia 19103 2Prism glasses expand the view for patients with hemianopia 19103 3Aon Study Finds Stability in Nationwide Liability Costs in the Long Term Health Care Sector 19100 1Aon Study Finds Stability in Nationwide Liability Costs in the Long Term Health Care Sector 19100 2Aon Study Finds Stability in Nationwide Liability Costs in the Long Term Health Care Sector 19100 3Hospital Association Moves Headquarters to Downtown Austin 19097 1Hospital Association Moves Headquarters to Downtown Austin 19097 2Independence Blue Cross Supports 2008 Senior Games 19094 1Independence Blue Cross Supports 2008 Senior Games 19094 2
...SS WIRE)--Apr 14, 2007 - In a late-breaker,present...ssociation,for the Study of the Liver (EASL), rese...m analysis of the PROVE 1 clinical trial,which is...y with,the investigational hepatitis C protease in...th pegylated interferon (peg-IFN) and,ribavirin (R...
...ted Phase 2 Study Now Underway at Nine,Centers, SA...regene,Inc., a biopharmaceutical company, today p...linical trial of CERE-120, a gene,therapy product ...sease, demonstrating a 36 percent (p<0.001) reduct...inistration, as measured,by the Unified Parkinson,...
Other Medicine Technology:Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C 2Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C 3Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C 4Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C 5Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C 6Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C 7Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C 8Ceregene Presents Long Term Follow-Up Data From Phase 1 Trial of,CERE-120 Demonstrating Improved Motor Function in Parkinson's,Patients 2Ceregene Presents Long Term Follow-Up Data From Phase 1 Trial of,CERE-120 Demonstrating Improved Motor Function in Parkinson's,Patients 3Ceregene Presents Long Term Follow-Up Data From Phase 1 Trial of,CERE-120 Demonstrating Improved Motor Function in Parkinson's,Patients 4
The dual lumen M.R.I. model is available with 1.0 or 1.2 mm inner diameter catheters (each lumen). ,Dual oval lumen catheters offer larger lumen equivalency while maintaining maximum catheter strengt
The standard-sized titanium port may be ordered with a silicone or polyurethane catheter. The silicone catheter is available with inner diameter sizes of 0.9, 1.0, 1.4, 1.6 mm. The polyurethane cathe
...nect to the CoolGard 3000 Thermal Regulation Syste...re input by the user. It remotely senses changes i...ts the temperature of the circulating saline withi...enance of temperature. The CoolGard 3000 represent...
Used for vascular access. Supplied sterile in peel-open packages. Intended for one-time use.
Medicine Products: